Systemic Sclerosis (Scleroderma)

A disease marked by fibrosis and vascular injury, systemic sclerosis remains difficult to treat.

Advances include:

• Nintedanib (Ofev®) for scleroderma-associated interstitial lung disease
• Investigational antifibrotic and immune-modulating agents